

Resource Summary Report

Generated by [ASWG](#) on Aug 9, 2026

Caspase-3 Antibody

RRID:AB_331439

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9662, RRID:AB_331439

Antibody Information

URL: http://antibodyregistry.org/AB_331439

Proper Citation: Cell Signaling Technology Cat# 9662, RRID:AB_331439

Target Antigen: Caspase-3

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: WB, W-S, IP, IHC-P
Consolidation on 11/2018: AB_10694681, AB_10839261, AB_331439.

Antibody Name: Caspase-3 Antibody

Description: This polyclonal targets Caspase-3

Target Organism: monkey, rat, mouse, human

Antibody ID: AB_331439

Vendor: Cell Signaling Technology

Catalog Number: 9662

Record Creation Time: 20250819T231224+0000

Record Last Update: 20250820T043711+0000

Ratings and Alerts

- Used for western blot assay by the Human Islet Research Network community.
Contact(s): [Decio Eizirik](#) - Human Islets Research Network <https://hirnetwork.org/>

No alerts have been found for Caspase-3 Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 354 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Ragosta MC, et al. (2026) The modulation of AUF1 regulates the R-loop resolution activating the immune response in DDR. *iScience*, 29(6), 115900.

Wang HL, et al. (2026) Loss-of-Function (G603R) Lrp10 Fails to Downregulate mRNA of Pathologic α -Synuclein and Causes Neurodegeneration of Substantia Nigra Dopaminergic Cells in Parkinson's Disease Knockin Mice. *Neurochemical research*, 51(3).

He J, et al. (2026) Differential regulation of hepatic macrophage fate by Chi3l1 in metabolic dysfunction-associated steatotic liver disease. *eLife*, 14.

Gunnala S, et al. (2026) Increased dietary levels of folic acid reduce survival and alters climbing behaviors 24h after hypoxia in male and female *Drosophila melanogaster*. *Behavioural brain research*, 499, 115941.

Ishino Y, et al. (2026) LPLAT11/MBOAT7-driven phosphatidylinositol remodeling ensures radial glial cell integrity in developing neocortex. *iScience*, 29(1), 114248.

Goulielmaki E, et al. (2026) IOA-244, a novel p110 α PI3K inhibitor, blocks breast tumour progression on either mono- or combined-therapy. *Cell death discovery*, 12(1).

Vavers E, et al. (2026) Simultaneous Expression of Sigma-1 Receptor and Tetraspanins Highlights Pathways of Receptor Sorting Into Extracellular Vesicles. *Journal of neurochemistry*, 170(4), e70426.

Ma X, et al. (2026) IAP-based biodegraders can convert necroptosis to apoptosis and eliminate cancer driving protein complexes. *Cell chemical biology*, 33(4), 553.

Liu K, et al. (2026) Hypoxia-driven lncRNA SHIELD promotes GPX4 translation and protects against ferroptosis in hepatocellular carcinoma. *Molecular cell*, 86(11), 2106.

Li N, et al. (2026) Lyn attenuates cisplatin-induced acute kidney injury by inhibition of RIPK1-mediated apoptosis and necroptosis. *Biochemical pharmacology*, 251(Pt 1), 118094.

He J, et al. (2026) Hyperactivated glycolysis drives spatially patterned Kupffer cell depletion in MASLD. *eLife*, 14.

Djamshidi M, et al. (2026) Protocol for enhancing CRISPR-Cas9 genome editing using histone deacetylase inhibition and engineered virus-like particle delivery. *STAR protocols*,

7(2), 104493.

Chauhan S, et al. (2026) Histone H3.3 ensures cell proliferation and genomic stability during myeloid cell development. *iScience*, 29(7), 116501.

Respekta-Dugosz N, et al. (2026) Asprosin expression and its role in regulating proliferation, cell cycle, and apoptosis in mouse hippocampal HT-22 cells. *Neuroscience*, 612, 308.

Ehlers L, et al. (2026) ADA2-deficient cells exhibit increased levels of cell death and metabolic disturbances. *Cell death discovery*, 12(1).

Chen X, et al. (2026) Glucose hypometabolism and hyperphosphorylated Tau synergistically drive neuronal necroptosis. *Neuron*.

Wang P, et al. (2026) Thimerosal Inhibits Tumor Malignant Progression through Direct Action and Enhancing the Efficacy of PD-1-Based Immunotherapy. *Oncology research*, 34(2), 20.

Doldi V, et al. (2026) FASN for diffuse malignant peritoneal mesothelioma: a prognostic biomarker after CRS+HIPEC and a therapeutic target. *Journal of translational medicine*, 24(1).

Rockfield SM, et al. (2026) Protein domain characterization reveals human MIC60 tolerates loss of helical bundle domain. *bioRxiv : the preprint server for biology*.

Ke H, et al. (2026) Knockout of PARP2 in T cells leads to spontaneous colitis with distinct segmental characteristics in PARP1-deficient mice. *Frontiers in immunology*, 17, 1741798.